Ticker Details
Ultragenyx Pharmaceutical Inc. Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development and commercialization of novel products for treatment of rare & ultra-rare diseases, with a focus on debilitating genetic diseases.
IPO Date:	January 31, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.3B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.53 | 2.49%
Avg Daily Range (30 D):	$0.45 | 1.82%
Avg Daily Range (90 D):	$0.49 | 2.14%

Institutional Daily Volume
Avg Daily Volume:	.57M
Avg Daily Volume (30 D):	1.32M
Avg Daily Volume (90 D):	1.67M

Trade Size
Avg Trade Size (Sh.):	67
Avg Trade Size (Sh.) (30 D):	58
Avg Trade Size (Sh.) (90 D):	66

Institutional Trades
Total Institutional Trades:	7,371
Avg Institutional Trade:	$2.87M
Avg Institutional Trade (30 D):	$4.08M
Avg Institutional Trade (90 D):	$4.21M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.65M
Avg Closing Trade (30 D):	$7.23M
Avg Closing Trade (90 D):	$7.4M
Avg Closing Volume:	92.83K

News

Apr 6, 2026 @ 2:51 PM ULTRAGENYX URGENT DEADLINE: Bragar Eagel & Squire,... Source: Bragar Eagel & Squire, P.C.

Apr 5, 2026 @ 11:29 PM TCPC IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL... Source: Rosen Law Firm

Apr 5, 2026 @ 10:37 PM RARE DEADLINE NOTICE: ROSEN, SKILLED INVESTOR COUN... Source: Rosen Law Firm

Apr 1, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx... Source: Bronstein, Gewirtz & Grossman Llc

Apr 1, 2026 @ 2:16 AM Ultragenyx Pharmaceutical Inc. Notice of April 6, ... Source: Kahn Swick & Foti, Llc

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-6.1	$-1.84	$-1.28
Diluted EPS	$-6.1	$-1.84	$-1.28
Revenue	$669.71M	$136M	$207.28M
Gross Profit
Net Income / Loss	$-608.92M	$-185M	$-128.56M
Operating Income / Loss	$-561.06M	$-169M	$-113.28M
Cost of Revenue
Net Cash Flow	$248M	$M	$222.12M
PE Ratio

Splits
Jan 17, 2014	15:47